1. Goldman, LS, Genel, M, Bezman, RJ, Slanetz, PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. J Am Med Asoc 1998; 279: 1100–1107.
2. Meltzer, H, Gatward, R, Goodman, R, et al. Mental Health of Children and Adolescents in Great Britain. The Stationery Office, London, 2000.
3. Hechtman, L, Greenfield, B. Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr Drugs 2003; 5: 787–794.
4. American Academy of Pediatrics SoA-DHD. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 1033–1044.
5. Vetter, VL, Elia, J, Erickson, C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008; 117: 2407–2423.
6. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr 2008; 29: 335.
7. Disorders ENoH. EUNETHYDIS ADHD Drug Safety Meeting. Paper presented at EUNETHYDIS ADHD Drug Safety Meeting, 10–13 March, 2009, Zurich.
8. Berger, S, Kugler, JD, Thomas, JA, Friedberg, DZ. Sudden cardiac death in children and adolescents: introduction and overview. Pediatr Clin North Am 2004; 51: 1201–1209.
9. Corrado, D, Basso, C, Schiavon, M, Thiene, G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339: 364–369.
10. Neuspiel, DR, Kuller, LH. Sudden and unexpected natural death in childhood and adolescence. J Am Med Assoc 1985; 254: 1321–1325.
11. Rappley, MD, Moore, JW, Dokken, D. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 2296–2298; author reply 2296–2298.
12. Wren, C. Sudden death in children and adolescents. Heart 2000; 83: 410–413.
13. Silka, MJ, Hardy, BG, Menashe, VD, Morris, CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 1998; 32: 245–251.
14. Sayal, K. Epidemiology of attention-deficit/hyperactivity disorder in the community. Br J Hosp Med (Lond) 2007; 68: 352–355.
15. Hovels-Gurich, HH, Konrad, K, Skorzenski, D, et al. Long-term neurodevelopmental outcome and exercise capacity after corrective surgery for tetralogy of Fallot or ventricular septal defect in infancy. Ann Thorac Surg 2006; 81: 958–966.
16. Shillingford, AJ, Glanzman, MM, Ittenbach, RF, Clancy, RR, Gaynor, JW, Wernovsky, G. Inattention, hyperactivity, and school performance in a population of school-age children with complex congenital heart disease. Pediatrics 2008; 121: e759–e767.
17. Winterstein, AG, Gerhard, T, Shuster, J, Johnson, M, Zito, JM, Saidi, A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007; 120: e1494–e1501.
18. Gould, MS, Walsh, BT, Munfakh, JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009; 166: 992–1001.
19. Kuehn, BM. Stimulant use linked to sudden death in children without heart problems. J Am Med Assoc 2009; 302: 613–614.
20. Schelleman, H, Bilker, WB, Strom, BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011; 127: 1102–1110.
21. Champeroux, P, Martel, E, Vannier, C, et al. The preclinical assessment of the risk for QT interval prolongation. Thérapie 2000; 55: 101–109.
22. Faber, TS, Zehender, M, Just, H. Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf 1994; 11: 463–476.
23. Labellarte, MJ, Crosson, JE, Riddle, MA. The relevance of prolonged QTc measurement to pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 2003; 42: 642–650.
24. Reingardiene, D, Vilcinskaite, J. QTc-prolonging drugs and the risk of sudden death. Medicina (Kaunas) 2007; 43: 347–353.
25. Wernicke, JF, Faries, D, Girod, D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729–740.
26. Wernicke, JF, Kratochvil, CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 (Suppl 12): 50–55.
27. Fuller, CM. Cost effectiveness analysis of screening of high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc 2000; 32: 887–890.
28. Denchev, P, Kaltman, JR, Schoenbaum, M, Vitiello, B. Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation 2010; 121: 1329–1337.
29. Tanaka, Y, Yoshinaga, M, Anan, R, et al. Usefulness and cost effectiveness of cardiovascular screening of young adolescents. Med Sci Sports Exerc 2006; 38: 2–6.
30. Corrado, D, Basso, C, Pavei, A, Michieli, P, Schiavon, M, Thiene, G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. J Am Med Assoc 2006; 296: 1593–1601.
31. Ubel, PA, DeKay, ML, Baron, J, Asch, DA. Cost-effectiveness analysis in a setting of budget constraints – is it equitable? N Engl J Med 1996; 334: 1174–1177.
32. Findling, RL, Short, EJ, Manos, MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001; 40: 525–529.
33. Samuels, JA, Franco, K, Wan, F, Sorof, JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006; 21: 92–95.
34. European Medicines Agency%. Guideline on Clinical Investigation of Medicinal Products for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD), 2009. European Medicine Agency, 2010. 7 Westferry Circus, Canary Wharf, London E14 4HB, UK.
35. Gutgesell, H, Atkins, D, Barst, R, et al. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1999; 99: 979–982.
36. Spencer, TJ, Greenbaum, M, Ginsberg, LD, Murphy, WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19: 501–510.
37. Lurbe, E, Cifkova, R, Cruickshank, JK, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 2009; 27: 1719–1742.